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Introduction
There is considerable anticipation of
future improvements in disease prevention
and treatment following recent advances
in genomics [1]. One aspect of genomics
that is receiving considerable interest is
epigenetics—the regulatory processes that
control the transcription of information
encoded in the DNA sequence into RNA
before their translation into proteins.
Programmed developmental changes and
the ability of the genome to register, signal,
and perpetuate environmental cues are
subsumed under the epigenetic banner
[2].
Genes are packaged into chromatin and
dynamic chromatin remodeling processes
are required for the initial step in gene
expression (transcription), achieved by
altering the accessibility of gene promoters
and regulatory regions [3]. Epigenetic
factors are responsible for this regulatory
process, the major components of which
are DNA methylation, histone modifica-
tions, and the action of small non-coding
RNAs (Figure 1). Unlike DNA sequence,
which is largely fixed throughout the
lifecourse, epigenetic patterns not only
vary from tissue to tissue but alter with
advancing age and are sensitive to envi-
ronmental exposures [4–7]. It is this
propensity for change that makes epige-
netic processes the focus of such interest,
as they lie at the interface of the
environment and co-ordinated transcrip-
tional control.
In rare developmental disorders, the
role of aberrant epigenetic processes is well
established [8]. Our focus here, however,
is on the potential role of epigenetic
processes in the context of common
complex disease. Tumor-specific changes
in epigenetic patterns are a hallmark of
numerous cancers, with analysis of the
epigenetic machinery beginning to feature
prominently in emerging cancer diagnos-
tics and therapies [9–11].
There is an increasing body of evidence
to demonstrate that epigenetic patterns are
altered by environmental factors known to
be associated with disease risk (e.g., diet,
smoking, alcohol intake, environmental
toxicants, stress) [7,8]; however, an im-
portant question remains to be resolved
in defining which epigenetic changes are a
secondary outcome of either exposure or
disease, and which lie on the causal
pathway linking the two. Without proven
causality, interventions to prevent or
treat common complex diseases based
upon epigenetic mechanisms will not be
fruitful. Conversely, regardless of causality,
defining a robust prospective relation-
ship between epigenetic patterns and
phenotypic traits may have application
in diagnostics or in identifying high-
risk individuals for non-epigenetic-based
interventions.
Measurement of Epigenetic
Patterns
Epigenetic patterns, including histone
modifications, microRNA (miRNA), and
DNA methylation, can be assessed in a
range of tissue types. As DNA methylation
assays on stored DNA samples are
straightforward, this has been extensively
studied [12]. Histone modification analysis
requires that DNA is maintained as intact
chromatin, whereas analysis of miRNA
requires a source of RNA. Planned
prospective collection for such analyses is
necessary, and both are costly to under-
take on sizable sample sets. The N-
terminal tails of the four core histones
(H2A, H2B, H3, and H4) commonly
exhibit post-translational modifications,
including acetylation, methylation, or
phosphorylation [13]. These histone mod-
ifications can be analysed following pre-
cipitation of chromatin, and subsequent
use of an antibody to a specific modifica-
tion e.g., methylation of histone 3, lysine 9
(H3-K9). miRNA expression levels can be
measured using the same principles and
methods as regular trranscriptomic analy-
sis (miRNA array or qPCR). DNA meth-
ylation can be assayed through genome-
wide approaches where the investigator is
interested in global changes or in identi-
fying regions of interest [14], or targeted
approaches that focus on DNA methyla-
tion at a particular locus or loci associated
with genes in a specific pathway [15].
These technologies are reviewed in detail
elsewhere [16].
The tissue specificity of epigenetic
patterns is a well-established phenomenon,
with variation between tissues within
individuals being greater than variation
between individuals [5]. Furthermore,
epigenetic dysregulation with advancing
age has been shown to be highly tissue
dependent [17]. Extrapolating epigenetic
information gleaned from DNA from
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blood or buccal cells to other tissue types is
therefore problematic. The correlation
between methylation patterns in different
tissues is complex and locus dependent,
but data that are beginning to emerge
suggest that epigenetic signatures on easily
accessible material such as circulating cells
have potential utility as biomarkers of
exposure or disease risk [18].
Epigenetic patterns are heritable across
cell divisions (mitosis) [19], but undergo
comprehensive but incompletely under-
stood reprogramming during meiosis [20].
Evidence that environmental exposures
can act across generations to influence
epigenetic patterns in offspring exist [21],
with maternal exposure to famine during
the perinatal period influencing offspring
DNA methylation in adulthood [22,23].
The quantitative importance of such
intergenerational epigenetic transmission
remains uncertain, and may have been
over-emphasized in comparison with the
theoretically less challenging but probably
more tractable and important intra-gener-
ational epigenetic influences [24].
Environmental Influences on
Epigenetic Patterns
Several other factors beyond tissue type
and age [4,5,17,25,26] are believed to
influence epigenetic patterns. Nutritional
factors modulate epigenetic marks in both
animal models and humans (reviewed by
[27]), with dietary sources of methyl
groups, including folate, choline, betaine,
methionine, and serine, which are re-
quired for DNA methylation [28,29],
having been most studied. In animal and
human studies these modulate epigenetic
patterns in disease and non-disease set-
tings. Other dietary components with
evidence for an effect on epigenetic
patterns relevant to the pathogenesis of
common complex diseases include the
influence of a high-fat diet on DNA
methylation [30] and various dietary
modifiers of histone deacetylase (HDAC)
activity such as isothiocyanates, butyrate,
and diallyl disulfide [31,32]. miRNA levels
have also been observed to be altered
following dietary modulation, with
miRNA expression in human muscle
being increased following a dietary chal-
lenge of essential amino acids [33].
The most widely studied lifestyle influ-
ence on epigenetic patterns is smoking. It
has been associated with global hypo-
methylation in DNA [34] as well as gene-
specific hypermethylation [35] in tumor
tissues in head and neck squamous cell
carcinoma (HNSCC). Animal models
suggest that epigenetic changes arise in
lung tissue following short-term exposure
to tobacco smoke condensate [36] and
precede histopathological changes. Expo-
sure to tobacco smoke is also believed to
alter expression of DNA methyltransferase
(DNMT) enzymes [37,38] and modulate
histone modifications, including acetyla-
tion and methylation [39]. In addition,
miRNAs have been proposed as modula-
tors of smoking-induced changes in gene
expression in human airway epithelium
[40], and studies in rodent models have
demonstrated that chemopreventive
agents can protect the lung tissue from
smoke exposure-induced changes in
miRNA expression [41]. Maternal ciga-
rette smoking during pregnancy influences
DNA methylation patterns in offspring
[42,43], pointing to a vulnerability of the
epigenome to environmental exposures
during the intrauterine period.
Animal studies have shown that chronic
alcohol consumption is associated with
reduced genomic DNA methylation in the
colon [44], although evidence from hu-
man studies is equivocal. Alcohol-induced
shifts in DNA methylation patterns could
arise through perturbation of one-carbon
metabolism and interference with methyl
group donation (reviewed by [45]). The
molecular actions of ethanol are also
thought to involve site-specific changes to
histone modifications, exemplified by a
recent study of alcohol exposure during
adolescence [46]. Epigenetic processes
could also influence patterns of alcohol
drinking, with emerging evidence suggest-
ing that alcohol-sensitive miRNAs control
the development of tolerance and subse-
quent alcohol addiction [47]. The alcohol-
related miRNA responses may in turn
reflect alcohol-induced changes in DNA
methylation [48].
Air pollutants such as air particulate
matter and airborne benzene exposure
levels have been associated with changes
in DNA methylation in genes involved in
inflammation and carcinogenesis [49,50].
Endocrine disruptors (vinclozilin, bisphe-
nol A), and various heavy metals (arsenic,
mercury, cadmium) are among other
compounds present in the environment
that have been implicated in epigenetic
changes, including altered histone methyl-
ation [21]. Most epigenetic studies of
environmental toxins have focused on the
potential of DNA methylation patterns as
biological markers of exposure rather than
establishing epigenetic mechanisms as
being causally related to a specific disease.
Studies have, however, suggested a role for
miRNAs in mediating the effects of
exposure to black carbon on disease [51].
Several infectious agents, including Hel-
icobacter pylori [52] and Epstein-Barr virus
[53], have been shown to induce epige-
netic changes, either directly or secondary
to inflammation. Epigenetic modulation is
recognized as an aetiological component
in chronic inflammatory diseases such as
rheumatoid arthritis and multiple sclerosis
[54]. Inflammation also plays an impor-
tant role in a wide range of diseases such
as cancers, obesity, and atopic disorders,
and epigenetic changes may be causal in
disease pathogenesis [54]. There is in-
creasing evidence that epigenetic mecha-
nisms contribute to the transcriptional
regulation of inflammatory responses [55].
Summary Points
N The epigenome records a variety of dietary, lifestyle, behavioral, and social cues,
providing an interface between the environment and the genome. Epigenetic
variation, whether genetically or environmentally determined, contributes to
inter-individual variation in gene expression and thus to variation in common
complex disease risk.
N Interventions based upon epigenetic agents, including DNA methyltransferase
inhibitors and histone deacetylase inhibitors, have been in clinical use for many
years, but their role outside treatment of specific cancers is not established.
N Epigenetic therapies will only be fruitful if epigenetic mechanisms are causally
related to the disease being treated. Evidence linking epigenetic variation to
specific disease phenotypes to date is lacking.
N Epidemiological approaches can be applied to help separate causal from non-
causal associations.
N We propose the development of a Mendelian randomization approach
(‘‘genetical epigenomics’’), which could help overcome the problems of
confounding and reverse causation (when an association between epigenetic
patterns and disease phenotype is observed but it is unknown whether the
disease is causing changes to the epigenome or epigenetic changes are causal
in disease pathogenesis).
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example of the influence of environmental
conditions (other than diet) on the epigen-
ome relates to maternal postnatal nurtur-
ing and epigenetically mediated alterations
to the hypothalamic-pituitary-adrenal re-
sponse to stress [56]. Variations in mater-
nal signals alter gene expression and
complex behavioral phenotypes in rodent
offspring through a well-defined mecha-
nism involving the epigenetic regulation of
the glucocorticoid receptor gene within
the target tissue. A further example of
modulation of epigenetic patterns in a
target tissue is that of increased histone
acetylation in human muscle biopsy tissue
following exercise [57], providing evidence
that chromatin remodeling might be
important in mediating longer-term re-
sponses to exercise. miRNA involvement
in exercise-induced changes to gene ex-
pression has also been reported [58].
Genetic Influences on
Epigenetic Patterns
Twin- and family-based studies have
demonstrated that variation in epigenetic
patterns, including both chromatin states
[59] and DNA methylation [25,60,61], is
heritable. Much inter-individual variation
in epigenetic patterns can be explained by
common genetic variation [62], with a
recent study estimating that 6.5% of the
variance in methylation at the IGF2
(insulin-like growth factor 2) locus could
be explained by five single nucleotide
polymorphisms (SNPs) [63]. A genome-
wide association study considering DNA
methylation in human brain tissue as a
quantitative trait identified both cis and
trans genetic effects upon DNA methyla-
tion (cytosine guanine dinucleotide [CpG])
sites, the predominant influences being in
cis, defined as SNPs influencing methyla-
tion at CpG sites within 1 Mb of them-
selves [64]. Similar cis effects have been
reported in whole blood DNA [25].
Figure 1. Epigenetic modifications. Chromosomes are composed of chromatin, consisting of DNA wrapped around eight histone protein units.
Each DNA-bound histone octamer is a nucleosome. Histone tails protruding from histone proteins are decorated with modifications, including
phosphorylation (Ph), methylation (Me), and acetylation (Ac). DNA molecules are methylated by the addition of a methyl group to carbon position 5
on cytosine bases when positioned adjacent to a guanine base (CpG sites), a reaction catalyzed by DNA methyltransferase enzymes. DNA methylation
maintains repressed gene activity. Transcription involves the conversion of DNA to messenger RNA (mRNA), which is usually repressed by DNA
methylation and histone deacetylation. mRNA is translated into a protein product, but this process can be repressed by binding of microRNA (miRNA)
to mRNA. Each miRNA binds to the mRNA of up to 200 gene targets. miRNAs can also be involved in establishing DNA methylation and may influence
chromatin structure by regulating histone modifiers.
doi:10.1371/journal.pmed.1000356.g001
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minants of DNA methylation, histone
modifications, and miRNA activity will
transform our understanding of the mech-
anisms involved in the establishment and
maintenance of epigenetic patterns, with
such genetic influences undoubtedly con-
tributing to observed inter-individual dif-
ferences in gene expression [65].
Despite the relatively large body of
evidence that disease-related environmen-
tal exposures are associated with epigenet-
ic alterations, there remains little compel-
ling data to support the link between
epigenetic variation and common complex
disease phenotypes (other than cancer).
Investigation of parent-of-origin effects on
risk of common complex disease have
suggested a role of perturbed DNA
methylation [66]. Adequately powered
studies relating epigenetic profiles to both
exposure and disease are in their infancy,
but it is highly likely that a myriad of such
associations will be identified, and the
major issue will be identifying meaningful
and useful associations within this tsunami
of data. Epigenetic measures are pheno-
typic, not genotypic, and as with pheno-
typic measures in general, non-causal
associations will be the rule rather than
the exception [67]. As with conventional
epidemiological investigations, separating
causal from non-causal associations will
become an important task (Figure 2).
‘‘Genetical Epigenomics’’:
Identifying Causal
Relationships between
Exposure, Epigenetic Patterns,
and Disease
Using germ-line genetic variation as a
proxy for environmental exposures pro-
vides a route to strengthening causal
inference within observational data [68–
70]. The rationale is that genetic variants
are not, in general, related to the socio-
economic, behavioral, and physiological
factors that confound associations in
conventional observational epidemiology
[67], nor are they altered by disease
processes and thus subject to reverse
causation. The Mendelian randomization
approach can be extended to the interro-
gation of epigenetic variation as potential
mediators of the influence of a modifiable
exposure on disease outcomes, and thus
appropriate targets for disease prevention.
Mendelian randomization methods can
be applied to many categories of environ-
mentally modifiable exposures to help
define whether their relationship with
phenotype is causal. For example, with
respect to behavioral factors, it has been
used in a proof-of-principle manner to
demonstrate associations of alcohol intake
with esophageal [71] and head and neck
cancers [72], as well as to considerably
strengthen evidence on the associations of
alcohol intake with blood pressure [73].
The method has particular promise when
applied to circulating intermediate pheno-
types, the manipulation of which can
potentially prevent disease. Again, as
proof-of-principle, an increasing number
of genetic variants that are associated with
low density lipoprotein-cholesterol (LDL-
C) level are also associated with coronary
artery disease (CAD) risk [67,74–76]
(Figure 3).
In a similar fashion, genetic variants
related to body mass index and obesity
have been shown to influence a wide
variety of metabolic, cardiovascular, and
bone-related traits, strengthening evidence
on the causal influence of adiposity in these
cases [77–80]. Conversely, genetic variants
associated with C-reactive protein (CRP)
level have not been found to predict insulin
resistance [80] or coronary heart disease
[81], casting doubt on the causal role of
CRP with respect to these conditions.
Figure 2. Defining the causal relationship between epigenetic patterns and
phenotype. Analysis of the respective relationships between DNA methylation (CpG), body
mass index (BMI), and cardiovascular disease (CVD) can help to inform the direction of causality.
An observed association between BMI and CpG and CpG and CVD will not decipher which of the
depicted scenarios apply.
doi:10.1371/journal.pmed.1000356.g002
Figure 3. Applying Mendelian randomi-
zation to define the causal relationship
between phenotype and disease. An
example based upon the report of Lintel-
Nietschke et al. (2008) [74] reporting the
association between a gene variant in the
LDLR gene with decreased low density lipo-
protein-cholesterol (LDL-C) levels and with a
reduced risk of coronary artery disease (CAD).
The variant can be used in a Mendelian
randomization approach to test the causal
relationship between LDL-C and CAD. If LDL-C
has a causal role in CAD, an association
between the LDLR gene variant and disease
risk would be seen (red dashed arrow). If LDL-
C levels are correlated with CAD risk but not
causal, then the gene variant will not show an
association with CAD risk. This will establish
whether reverse causation is at play and
remove the potential confounding influence
of factors such as smoking and nutritional
status.
doi:10.1371/journal.pmed.1000356.g003
PLoS Medicine | www.plosmedicine.org 4 October 2010 | Volume 7 | Issue 10 | e1000356In the field of gene expression studies,
identifying causal processes within a mul-
titude of associations is at least as prob-
lematic as in observational epidemiological
studies. For example, the majority of gene
expression signatures in adipose tissue, and
in high proportions (up to 10%) in blood,
have been found to be related to obesity
[82]. Methods equivalent to the Mende-
lian randomization approach we propose
here (sometimes called ‘‘genetical geno-
mics’’ [83] in the context of gene expres-
sion studies) have been applied to separate
causal transcription effects from those
generated by reverse causation [82]. This
is facilitated by strong cis effects on gene
expression, which allows isolation of spe-
cific loci influencing transcript level. The
identification of strong cis effects in a
genome-wide association study analysis of
methylation patterns [64] provides en-
couragement that these methods can be
extended to investigate the causal influ-
ences of epigenetic signatures in what
could be called ‘‘genetical epigenomics’’.
As a hypothetical example of how this
approach could be applied, we will
consider alcohol intake and HNSCC. It
is likely that alcohol intake would be
associated with a wide range of epigenetic
changes, although at least some (and
probably many) of these associations could
reflect confounding by the many other
factors related to alcohol consumption.
Similarly, HNSCC could be related to a
multitude of epigenetic changes, which
could arise through reverse causation (the
disease influencing the epigenetic patterns)
or confounding (factors associated with
HNSCC risk influencing the epigenetic
patterns). If the epigenetic processes are to
be targeted as a component of disease
prevention they must be causally associat-
ed with HNSCC, and for them to mediate
the effect of alcohol intake on HNSCC risk
they need to be responsive to changes in
alcohol intake. Observational data dem-
onstrating an association of alcohol intake
with a particular epigenetic profile exists,
but the association of this profile with
HNSCC risk does not, of course, establish
causality. As depicted in Figure 4, Men-
delian randomization approaches could be
applied to this scenario.
Epigenomic Modifiers and the
Prospects for Future
Treatments
It can be argued that mitotically stable
changes in gene expression are very likely to
underlie the development of virtually all
disease (in the same way as they are an
essential component in the process of the
development of an organism [84]), and as
definitions of epigenetics incorporate such
changes, they automatically fall within the
field’s remit. Once epigenetic mechanisms,
even if only contributory, are unequivocally
implicated in disease pathogenesis, the
prospect of epigenomic-based therapies
becomes a realistic possibility. A wide range
of pharmacological agents that target the
epigenome, including DNMT inhibitors
and HDAC inhibitors, are used in clinical
practice, largely as anti-cancer treatments
[11]. However, these agents require further
development to enhance the specificity of
their pleiotropic effects, and evaluation of
their efficacy in a non-cancer setting is
essential. Combination therapies involving
DNMT inhibitors or HDACs being em-
ployed with other agents are an active
avenue of inquiry. miRNAs are also emerg-
ing as a promising technology in drug
development following an increasing under-
standing of their biogenesis and function.
The links between miRNA expression and
common complex disease are growing,
providing a greater impetus to pursue this
useful tool for the targeted modulation of
gene regulation. As with other epigenetic
signatures, their utility might also lie in
disease diagnosis and prognosis [85].
Figure 4. Incorporating epigenetic information in a Mendelian randomization
framework. (A) Alcohol exposure is associated with risk of head and neck squamous cell
carcinoma (HNSCC) and this may be mediated by altered DNA methylation (CpG). The
relationship between alcohol exposure and HNSCC is potentially confounded by factors such as
socio-economic position, which correlate with both exposure and disease. A common variant in
ADH1B can be used as an unconfounded, genetic proxy for alcohol exposure, and if this SNP is
associated with CpG (either locally or more widely across the genome), it would lend support to
the hypothesis that alcohol intake causally influences DNA methylation. However, showing
associations of these epigenetic measures with HNSCC does not demonstrate causality of either
alcohol or CpG on HNSCC, as either or both associations (alcoholRHNSCC and CpGRHNSCC)
could be confounded or alcohol could influence HNSCC through another pathway (dashed line).
(B) To investigate this, another Mendelian randomization experiment could be undertaken using
an SNP known to have a cis influence on loci-specific DNA methylation. If an association were
observed between this SNP and both CpG and HNSCC, this would support a role for DNA
methylation in the causation of HNSCC.
doi:10.1371/journal.pmed.1000356.g004
PLoS Medicine | www.plosmedicine.org 5 October 2010 | Volume 7 | Issue 10 | e1000356Conclusion
Through examining the role of envi-
ronmental factors in causing variation in
epigenetic patterns (exposure/epigen-
otype) and ultimately exploring the
causal impact of epigenotype on disease
outcomes (epigenotype/disease) using
genetical epigenomics and other meth-
ods, progress towards epigenetic inter-
ventions can be made. As genome-wide
association studies and other approaches
identify robust associations between genetic
variants and epigenetic patterns, possibilities
for elucidating causal pathways and predict-
ing the effect of manipulation—through
environmental (including lifestyle) modifica-
tion or pharmacotherapeutic means—is
considerable.Inthisway,epigeneticmarkers
may become targets for modification as well
as biomarkers for exposure and disease risk.
The International Human Epigenome Con-
sortium is poised to invest millions of dollars
to map 1,000 reference epigenomes in a
range of normal tissues and define the level
of variation that exists between individuals
[86]. The field of epigenetics in relation to
common complex disease will undoubtedly
continue to be the focus of much attention,
and its progress, now that it has passed the
starting line, will be followed with consider-
able interest.
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